Japan's Toho faces court test of poison pill tactic against activists

• A record 10 contingency-based poison pills targeting specific investors were adopted in Japan last year, often preventing activist funds from raising stakes beyond roughly 20%
• 3D Investment Partners argues the defense is invalid since its 27% stake does not constitute a threat to management control under Toho's own criteria
• Critics warn such measures against non-control-seeking investors risk entrenching management and undermining Japan's corporate governance reforms initiated under former Prime Minister Shinzo Abe

Summary

Singapore-based hedge fund 3D Investment Partners has filed a court injunction with the Tokyo District Court to block Japanese drug wholesaler Toho Holdings' poison pill defense mechanism, marking a significant legal challenge to corporate anti-activist tactics in Japan.

Key Details:

• 3D Investment Partners, Toho's largest shareholder, seeks to prevent the company from deploying takeover defenses against its position
• The activist fund claims it holds a 27% stake and has no intention of acquiring management control
• 3D argues the 27% ownership falls below the threshold Toho established for effective veto power, meaning the poison pill trigger—a threat to management control—doesn't apply

Market Context:

Japan has witnessed a surge in contingency-based poison pills targeting specific investors, with advisory firm IR Japan reporting a record 10 such measures adopted in the previous year. These tactics typically aim to prevent activist funds from exceeding roughly 20% ownership stakes.

The defensive strategies represent a shift from Japan's earlier "pre-warning" poison pills, which declined following corporate governance reforms under former Prime Minister Shinzo Abe.

Implications:

Critics argue these anti-activist measures entrench management and undermine corporate governance improvements. Professor Manabu Matsunaka of Nagoya University warns that allowing such defenses could weaken capital market discipline on management.

The court case could establish important precedent on whether Japanese companies can legitimately deploy poison pills against activist investors not seeking outright control. While government guidelines permit such measures to allow time for shareholder consideration, the growing use against minority activists raises governance concerns for investors monitoring Japanese market reforms.